文献速递造血干细胞移植与细胞治疗

阿巴西普联合钙调神经磷酸酶抑制剂/甲氨蝶呤预防急性GVHD的II期试验

Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.
PubMed 文献 · J Clin Oncol · 2021-01-15

ABA2是一项II期试验,评估在钙调神经磷酸酶抑制剂/甲氨蝶呤方案基础上加用阿巴西普(T细胞共刺激阻断剂)预防无关供者造血干细胞移植后的急性GVHD。研究包含随机双盲安慰剂对照的8/8 HLA相合层(142例)和单臂的7/8 HLA不合层(43例,对比CIBMTR对照)。结果显示阿巴西普安全性良好,降低了3-4级急性GVHD并改善无严重GVHD生存,尤其在HLA不合移植中获益显著。

核心结论

  • 在无关供者造血干细胞移植中加用阿巴西普是安全的,可降低急性GVHD并改善无严重GVHD生存。
  • 阿巴西普可能显著改善急性GVHD相关移植结局,对HLA不合移植获益尤为明显。

研究设计与样本

  • ABA2为II期试验,纳入成人及儿童血液恶性肿瘤患者,分两个层。
  • 随机双盲安慰剂对照层:8/8 HLA相合无关供者,比较CNI/MTX+阿巴西普与CNI/MTX+安慰剂,共142例,中位随访716天。
  • 单臂层:7/8 HLA不合无关供者,CNI/MTX+阿巴西普对比CNI/MTX的CIBMTR对照,共43例,中位随访708天。
  • 主要终点为+100天3-4级急性GVHD,关键次要终点为+180天无严重GVHD生存。
  • 样本量基于预测阿巴西普将3-4级AGVHD从20%降至10%(8/8层)和从30%降至10%(7/8层),采用II期试验推荐的较高I类错误率0.2计算。

主要发现

  • 免疫学分析显示阿巴西普治疗患者T细胞活化得到控制。

临床怎么用

  • 对于接受无关供者造血干细胞移植的患者,可考虑在CNI/MTX基础上加用阿巴西普以预防急性GVHD。
  • HLA不合(7/8)无关供者移植患者可能从阿巴西普联合预防中获得更显著的急性GVHD预防获益。

局限性

  • 7/8不合层为单臂设计,对照为非随机匹配的CIBMTR历史队列。
  • 样本量基于II期试验推荐的较高I类错误率0.2计算。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in particularly high mortality after HLA-mismatched transplantation. There are no approved agents for AGVHD prevention, underscoring the critical unmet need for novel therapeutics. ABA2 was a phase II trial to rigorously assess safety, efficacy, and immunologic effects of adding T-cell costimulation blockade with abatacept to calcineurin inhibitor (CNI)/methotrexate (MTX)-based GVHD prophylaxis, to test whether abatacept could decrease AGVHD. METHODS: ABA2 enrolled adults and children with hematologic malignancies under two strata: a randomized, double-blind, placebo-controlled stratum (8/8-HLA-matched URD), comparing CNI/MTX plus abatacept with CNI/MTX plus placebo, and a single-arm stratum (7/8-HLA-mismatched URD) comparing CNI/MTX plus abatacept versus CNI/MTX CIBMTR controls. The primary end point was day +100 grade 3-4 AGVHD, with day +180 severe-AGVHD-free-survival (SGFS) a key secondary end point. Sample sizes were calculated using a higher type-1 error (0.2) as recommended for phase II trials, and were based on predicting that abatacept would reduce grade 3-4 AGVHD from 20% to 10% (8/8s) and 30% to 10% (7/8s). ABA2 enrolled 142 recipients (8/8s, median follow-up = 716 days) and 43 recipients (7/8s, median follow-up = 708 days). RESULTS: In 8/8s, grade 3-4 AGVHD was 6.8% (abatacept) versus 14.8% (placebo) (P = .13, hazard ratio = 0.45). SGFS was 93.2% (CNI/MTX plus abatacept) versus 82% (CNI/MTX plus placebo, P = .05). In the smaller 7/8 cohort, grade 3-4 AGVHD was 2.3% (CNI/MTX plus abatacept, intention-to-treat population), which compared favorably with a nonrandomized matched cohort of CNI/MTX (30.2%, P < .001), and the SGFS was better (97.7% v 58.7%, P < .001). Immunologic analysis revealed control of T-cell activation in abatacept-treated patients. CONCLUSION: Adding abatacept to URD HCT was safe, reduced AGVHD, and improved SGFS. These results suggest that abatacept may substantially improve AGVHD-related transplant outcomes, with a particularly beneficial impact on HLA-mismatched HCT.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Watkins B, Qayed M, McCracken C, et al. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. J Clin Oncol. 2021. PMID: 33449816. doi:10.1200/JCO.20.01086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。